175 related articles for article (PubMed ID: 35452143)
1. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
Jouzier C; Cherait A; Cony-Makhoul P; Hamel JF; Veloso M; Thepot S; Cluzeau T; Stamatoullas A; Garnier A; Guerci-Bresler A; Dimicoli-Salazar S; Pica GM; Cheze S; Santana C; Chermat F; Fenaux P; Park S
Transfusion; 2022 May; 62(5):961-973. PubMed ID: 35452143
[TBL] [Abstract][Full Text] [Related]
2. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
3. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Buckstein R; Chodirker L; Yee KWL; Geddes M; Leitch HA; Christou G; Banerji V; Leber B; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Parmentier A; Thambipillai A; Tang D; Westcott C; Cameron C; Spin P
Leuk Lymphoma; 2023 Mar; 64(3):651-661. PubMed ID: 36606533
[TBL] [Abstract][Full Text] [Related]
4. Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy.
Wong CAC; Leitch HA
Leuk Res; 2019 Aug; 83():106170. PubMed ID: 31229803
[TBL] [Abstract][Full Text] [Related]
5. Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates.
Durairaj S; Chew S; Hyslop A; Keenan N; Groves MJ; Tauro S
Am J Hematol; 2011 May; 86(5):406-10. PubMed ID: 21523799
[TBL] [Abstract][Full Text] [Related]
6. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
7. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
9. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
10. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
11. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Jabbour E; Kantarjian HM; Koller C; Taher A
Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
[TBL] [Abstract][Full Text] [Related]
12. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and treatment of anemia and secondary iron overload in patients with a myelodysplastic syndrome: Real-world data from a multicenter cohort study.
de Roij van Zuijdewijn CLM; Westerweel PE; Schipperus MR; Pruijt JFM; van de Loosdrecht AA; Beeker A
Transfus Clin Biol; 2023 Aug; 30(3):314-318. PubMed ID: 37061177
[TBL] [Abstract][Full Text] [Related]
15. Estimation of economic costs associated with transfusion dependence in adults with MDS.
Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
[TBL] [Abstract][Full Text] [Related]
16. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.
Rozema J; van Roon EN; Kibbelaar RE; Veeger NJGM; Slim CL; de Wit H; Hoogendoorn M;
Transfusion; 2021 Oct; 61(10):2877-2884. PubMed ID: 34480360
[TBL] [Abstract][Full Text] [Related]
17. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
Garcia-Manero G; Almeida A; Giagounidis A; Platzbecker U; Garcia R; Voso MT; Larsen SR; Valcarcel D; Silverman LR; Skikne B; Santini V
BMC Hematol; 2016; 16():12. PubMed ID: 27148452
[TBL] [Abstract][Full Text] [Related]
18. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
19. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Buckstein R; Chodirker L; Mozessohn L; Yee KWL; Geddes M; Zhu N; Shamy A; Leitch HA; Christou G; Banerji V; Brian L; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Delage R; Parmentier A; Thambipillai A; Siddiqui M; Westcott C; Cameron C; Mamedov A; Spin P; Tang D
Leuk Lymphoma; 2022 Dec; 63(13):3165-3174. PubMed ID: 36095125
[TBL] [Abstract][Full Text] [Related]
20. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
